rethinkPeptides Search
Menu
Home / Research library
Study breakdown

GLP-1 drugs effectively manage pasireotide-induced hyperglycemia in acromegaly patients

RPEP-137482025Taki, Yuki; Kono, Takashi; Matsuda, Tatsuma; Kozu, Ryunosuke; Fujimoto, Masanori; Sakuma, Ikki; Hashimoto, Naoko; Horiguchi, Kentaro; Higuchi, Yoshinori; Tanaka, Tomoaki
evidence
The takeaway

Two acromegaly cases demonstrate GLP-1 receptor agonists (dulaglutide, semaglutide) effectively manage pasireotide-induced hyperglycemia, with CGM enabling early detection of glycemic fluctuations during somatostatin analogue therapy.

GLP-1 counters somatostatin hyperglycemia

GLP-1 agonists effectively managed pasireotide-induced hyperglycemia in acromegaly patients, with CGM guiding therapy optimization

What the researchers found

Case 1: rapid postprandial hyperglycemia → managed with dulaglutide + CGM. Case 2: long-term dose-dependent glycemia → controlled by sequential GLP-1RAs including semaglutide. CGM: essential for early detection. GLP-1RAs: effective for SSTR5-mediated hyperglycemia.

Why it matters

Pasireotide is an important treatment for acromegaly but hyperglycemia limits its use. Demonstrating that GLP-1 drugs effectively counteract this side effect could enable more patients to benefit from pasireotide.

How the study worked

Two-case report with literature review. CGM monitoring. Sequential GLP-1RA therapy.

What this study cannot tell us

Two cases only. East Asian population. No randomized comparison. CGM not universally available.

How to read the evidence

Two case reports with literature review. Practical clinical guidance.

When this study was published

Published in 2025.

The bigger picture

This illustrates a practical intersection of two peptide drug classes: somatostatin analogues (causing hyperglycemia) and GLP-1 agonists (treating it). This combination approach could optimize acromegaly treatment.

Questions still open

  • Should GLP-1 drugs be routinely co-prescribed with pasireotide?
  • Which GLP-1 drug is optimal for SSTR5-mediated hyperglycemia?
  • Does CGM improve outcomes in all pasireotide-treated patients?

Common questions

Why does pasireotide cause high blood sugar?
Pasireotide blocks somatostatin receptor 5 (SSTR5) on pancreatic beta-cells, which inhibits insulin secretion. This causes hyperglycemia in many patients. GLP-1 drugs like semaglutide counteract this by stimulating insulin release through a different pathway (GLP-1 receptor), effectively managing the hyperglycemia.
Can you take both somatostatin and GLP-1 drugs?
Yes, these cases demonstrate that combining pasireotide (for acromegaly control) with GLP-1 drugs (for blood sugar management) is safe and effective. Continuous glucose monitoring helps optimize the combination by detecting glycemic fluctuations early.

Read the original research

Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.

Endocrine journal, 72(4), 421-435

View on PubMed ↗Publisher’s paper ↗

Citation

Taki, Yuki; Kono, Takashi; Matsuda, Tatsuma; Kozu, Ryunosuke; Fujimoto, Masanori; Sakuma, Ikki; Hashimoto, Naoko; Horiguchi, Kentaro; Higuchi, Yoshinori; Tanaka, Tomoaki. (2025). Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.. Endocrine journal, 72(4), 421-435. https://doi.org/10.1507/endocrj.EJ24-0548